N. Gebbia

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
N Gebbia, N. Gebbia, Nicola Gebbia
Publication record
175 papers · 6,676 citations · H-index 36

PAPERS

Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer
201612 citationsauthor #59
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
20158 citationsauthor #243
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.
20143 citationsauthor #10
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience.
201213 citationsauthor #7
EGFR genomic alterations in cancer: prognostic and predictive values.
201147 citationsauthor #10
Subject Index Vol. 77, Suppl. 1, 2009
20100 citationsauthor #62
PML down‐regulation in soft tissue sarcomas
20105 citationsauthor #10
The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway
201056 citationsauthor #6
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
201024 citationsauthor #16
PML expression in soft tissue sarcoma: prognostic value in alkilating agents/anthracyclin based first line therapy
20100 citationsauthor #9
Anti-endothelin drugs in solid tumors
201019 citationsauthor #6
5th European Workshop on Immune-Mediated Inflammatory Diseases
20100 citationsauthor #9
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results
20100 citationsauthor #10
Bortezomib: a new pro-apoptotic agent in cancer treatment.
201033 citationsauthor #6
miR‐20b modulates VEGF expression by targeting HIF‐1α and STAT3 in MCF‐7 breast cancer cells
2010227 citationsauthor #8
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
2010114 citationsauthor #9
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
2010147 citationsauthor #10
Gemcitabine‐based doublets versus single‐agent therapy for elderly patients with advanced nonsmall cell lung cancer
200926 citationsauthor #7
Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
200912 citationsauthor #3
Residual Vein Thrombosis Improves Screening for Occult Cancer: Results On 537 Patients with Idiopathic Deep Vein Thrombosis.
20090 citationsauthor #8
Palliative splenic irradiation in primary and post PV/ET myelofibrosis: outcomes and toxicity of three radiation schedules
20097 citationsauthor #10
Antiproliferative Agents That Interfere with the Cell Cycle at the G1→S Transition: Further Development and Characterization of a Small Library of Stilbene‐Derived Compounds
200812 citationsauthor #7
Determination of stilbenes in Sicilian pistachio by high-performance liquid chromatographic diode array (HPLC-DAD/FLD) and evaluation of eventually mycotoxin contamination
200848 citationsauthor #6
Splenic Irradiation (SI) in Myelofibrosis: Outcomes and Toxicity of Three Radiation Schedule
20081 citationsauthor #5
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
200866 citationsauthor #8
Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.
200873 citationsauthor #2
Emotional expression and coping style in female breast cancer.
200733 citationsauthor #6
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis.
200749 citationsauthor #9
Detection of polyphenolic compounds (stilbenes and flavonoids) in natural products.
20072 citationsauthor #6
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features.
200764 citationsauthor #13
Aurora-A overexpression as an early marker of reﬂux-related columnar mucosa and Barrett (cid:1) s oesophagus
20070 citationsauthor #10
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
200738 citationsauthor #5
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
200739 citationsauthor #9
Papillary Carcinomas of the Thyroid ≤1 cm and Their Paired Lymph Node Metastases
20075 citationsauthor #5
Alexithymia and copyng style in women going to visit in a breast cancer center
20070 citationsauthor #13
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
200782 citationsauthor #8
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis.
20070 citationsauthor #7
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses
200727 citationsauthor #16
Cancer-Related Venous Thrombosis: Residual Vein Thrombosis Improves Screening for Occult Cancer.
20070 citationsauthor #7
Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus.
200716 citationsauthor #10
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
2007465 citationsauthor #10
BRAFV600E mutation and p27kip1 expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases
200773 citationsauthor #5
[Clinical guidelines for the management of gastrointestinal stromal tumors].
20065 citationsauthor #16
Ductal Lavage: a valid method of risk assessment and of early diagnosis in breast cance
20060 citationsauthor #34
Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism.
200667 citationsauthor #11
New potential circulating markers for the therapeutic monitoring of metastatic bone disease.
20060 citationsauthor #12
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.
200633 citationsauthor #9
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second‐line treatment in relapsed ovarian carcinoma
200616 citationsauthor #11
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
200615 citationsauthor #8
Caretakers and Gatekeepers
20062 citationsauthor #5
Angiogenesis modiﬁcations related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients
20060 citationsauthor #9
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
200653 citationsauthor #10
Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.
200671 citationsauthor #8
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer
2006110 citationsauthor #5
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients
20060 citationsauthor #20
Ductal lavage: a way of carefully tracing the breast-secreting duct
20061 citationsauthor #13
Effects of Propolis in cancer cells
20060 citationsauthor #10
A Case of Guillain-Barré Syndrome in a Patient with Non Small Cell Lung Cancer Treated with Chemotherapy
20068 citationsauthor #7
A Case of Squamocellular Uterine Cervix Carcinoma Metastatic to the Skin with Enterocutaneous Fistula
20060 citationsauthor #4
Angiogenesis modifications are predictive of response and outcome in heavily pretreated advanced colorectal cancer patients during therapy with cetuximab plus irinotecan.
20060 citationsauthor #9
Clinical Presentation and Treatment of Gastrointestinal Stromal Tumors
20066 citationsauthor #10
TP53 mutations and S‐phase fraction but not DNA‐ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma
200612 citationsauthor #14
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer
20068 citationsauthor #15
Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines.
2005135 citationsauthor #14
Tumor markers in urogynaecological tumors.
20050 citationsauthor #9
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer
200530 citationsauthor #12
TP 53 Mutations and S-Phase Fraction but not DNA-Ploidy Are Independent Prognostic Indicators in Laryngeal Squamous Cell Carcinoma
20051 citationsauthor #14
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
200531 citationsauthor #5
Imatinib Mesilato:Profilo del farmaco
20050 citationsauthor #1
Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule
20052 citationsauthor #11
Overexpression of cyclin D1 and interaction between p27Kip1 and tumour thickness predict lymph node metastases occurrence in lower lip squamous cell carcinoma.
200514 citationsauthor #6
Anticancer Drugs Targeting the Apoptotic Pathway
20052 citationsauthor #2
Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer: A Phase II Study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106)
200542 citationsauthor #8
Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer.
20053 citationsauthor #7
Overexpression of cyclin D 1 and interaction between p 27 Kip 1 and tumour thickness predict lymph node metastases occurrence in lower lip squamous cell carcinoma
20051 citationsauthor #6
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
2005414 citationsauthor #6
Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer
20052 citationsauthor #4
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
2005725 citationsauthor #6
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck
20052 citationsauthor #3
Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells.
2005166 citationsauthor #8
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.
2005453 citationsauthor #86
The Use of Zoledronic Acid in Patients with Bone Metastases from Prostate Carcinoma: Effect on Analgesic Response and Bone Metabolism Biomarkers
200527 citationsauthor #13
Studies on the apoptotic activity of natural and synthetic retinoids: discovery of a new class of synthetic terphenyls that potently support cell growth and inhibit apoptosis in neuronal and HL-60 cells.
200530 citationsauthor #13
Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient.
20046 citationsauthor #10
Zoledronic acid-induced variations in MMP-2, MMP-9 and uPA plasma concentrations in patients with metastatic bone disease
20040 citationsauthor #13
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation
20040 citationsauthor #31
TP53 in gastric cancer: Mutations in the L3 loop and LSH motif DNA‐binding domains of TP53 predict poor outcome
200431 citationsauthor #13
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients
20042 citationsauthor #4
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
200428 citationsauthor #6
Lysosomal alterations in heart and liver of mice treated with doxorubicin
200413 citationsauthor #1
GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY
20043 citationsauthor #9
Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications
200489 citationsauthor #5
Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation.
20045 citationsauthor #7
A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004
20040 citationsauthor #20
The occurrence of the stilbene piceatannol in some wines from Sicily
20033 citationsauthor #1
STAT proteins: From normal control of cellular events to tumorigenesis
2003644 citationsauthor #6
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Grupp
200361 citationsauthor #12
Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo
2003233 citationsauthor #2
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.
2003115 citationsauthor #2
Nm23-H1 expression does not predict clinical survival in colorectal cancer patients.
200312 citationsauthor #22

TIMELINE

1973 3 citations

1974 1 citations

1975 0 citations

1976 17 citations

1979 4 citations

1983 5 citations

1985 9 citations

1987 12 citations

1988 174 citations

1989 7 citations

1990 33 citations

1991 15 citations

1992 130 citations

1993 108 citations

1994 69 citations

1995 42 citations

1996 87 citations

1997 116 citations

1998 4 citations

1999 7 citations

2000 69 citations

2001 45 citations

2002 143 citations

2003 1,068 citations

2004 177 citations

2005 2,080 citations

2006 407 citations

2007 893 citations

2008 200 citations

2009 45 citations

2010 625 citations

2011 47 citations

2012 13 citations

2014 3 citations

2015 8 citations

2016 12 citations

N. Gebbia

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT